Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group

MLA

Joaquin Herrero, et al. “Efficacy of the Combination of Rituximab-Bendamustine as a Second-Line Treatment in Patients with Follicular Lymphoma Who Progress after Immunochemotherapy: A Phase II Trial of the Spanish Lymphoma Oncology Group.” Leukemia & Lymphoma, vol. 60, Dec. 2018, pp. 1576–79. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........2d58ee0ec692c9694f082990415bc9d5&authtype=sso&custid=ns315887.

APA

Joaquin Herrero, Francisco R García-Arroyo, Antonio Rueda, Cristina Quero, Delvys Rodriguez-Abreu, Ana Blasco, Marta Llanos, María José Casanova, Natividad Martínez-Banaclocha, Jesús Alfaro, David Aguiar, Ruth Alvarez, Luis Merino, Virginia Calvo, & Mariano Provencio. (2018). Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group. Leukemia & Lymphoma, 60, 1576–1579.

Chicago

Joaquin Herrero, Francisco R García-Arroyo, Antonio Rueda, Cristina Quero, Delvys Rodriguez-Abreu, Ana Blasco, Marta Llanos, et al. 2018. “Efficacy of the Combination of Rituximab-Bendamustine as a Second-Line Treatment in Patients with Follicular Lymphoma Who Progress after Immunochemotherapy: A Phase II Trial of the Spanish Lymphoma Oncology Group.” Leukemia & Lymphoma 60 (December): 1576–79. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........2d58ee0ec692c9694f082990415bc9d5&authtype=sso&custid=ns315887.